ArticleCancer biology & therapy2015

Pre-clinical activity of PR-104 as monotherapy and in combination with sorafenib in hepatocellular carcinoma.

Maria R Abbattista et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.